Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.

However, despite the small sample size, we were able to demonstrate statistically significant outcomes in patients who were initiated on both GLP1 RA and SGLT2i’s, and we were trending toward significance with the GLP1s plus Metformin sample as well as with the total population.

also in 148 other papers